Barrow Neurological Institute at St. Joseph's Hospital and Medical Center

Barrow - St. Joseph's Scholarly Commons
Neurology
2013

Phase III Randomized Trial Comparing the Efficacy of Cediranib
as Monotherapy and in Combination With Lomustine Versus
Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor
Paul Mulholland
Bart Neyns
L. Burt Nabors
Mario Campone

See next page for additional authors

Follow this and additional works at: https://scholar.barrowneuro.org/neurology

Recommended Citation
Batchelor, Tracy T.; Mulholland, Paul; Neyns, Bart; Nabors, L. Burt; Campone, Mario; Wick, Antje; Mason,
Warren; Mikkelsen, Tom; Phuphanich, Surasak; Ashby, Lynn S.; DeGroot, John; Gattamaneni, Rao; Cher,
Lawrence; Rosenthal, Mark; Payer, Franz; Jürgensmeier, Juliane M.; Jain, Rakesh K.; Sorensen, A. Gregory;
Xu, John; and al., et, "Phase III Randomized Trial Comparing the Efficacy of Cediranib as Monotherapy and
in Combination With Lomustine Versus Lomustine Alone in Patients With Recurrent Glioblastoma" (2013).
Neurology. 145.
https://scholar.barrowneuro.org/neurology/145

This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been
accepted for inclusion in Neurology by an authorized administrator of Barrow - St. Joseph's Scholarly Commons.
For more information, please contact suefue.espe@commonspirit.org.

Authors
Tracy T. Batchelor, Paul Mulholland, Bart Neyns, L. Burt Nabors, Mario Campone, Antje Wick, Warren
Mason, Tom Mikkelsen, Surasak Phuphanich, Lynn S. Ashby, John DeGroot, Rao Gattamaneni, Lawrence
Cher, Mark Rosenthal, Franz Payer, Juliane M. Jürgensmeier, Rakesh K. Jain, A. Gregory Sorensen, John
Xu, and et al.

This article is available at Barrow - St. Joseph's Scholarly Commons: https://scholar.barrowneuro.org/neurology/145

VOLUME 31 䡠 NUMBER 26 䡠 SEPTEMBER 10 2013

JOURNAL OF CLINICAL ONCOLOGY

O R I G I N A L

R E P O R T

Phase III Randomized Trial Comparing the Efficacy of
Cediranib As Monotherapy, and in Combination With
Lomustine, Versus Lomustine Alone in Patients With
Recurrent Glioblastoma
Tracy T. Batchelor, Paul Mulholland, Bart Neyns, L. Burt Nabors, Mario Campone, Antje Wick,
Warren Mason, Tom Mikkelsen, Surasak Phuphanich, Lynn S. Ashby, John DeGroot, Rao Gattamaneni,
Lawrence Cher, Mark Rosenthal, Franz Payer, Juliane M. Jürgensmeier, Rakesh K. Jain, A. Gregory Sorensen,
John Xu, Qi Liu, and Martin van den Bent
Author affiliations appear at the end of
this article.
Published online ahead of print at
www.jco.org on August 12, 2013.
Supported by AstraZeneca.
Presented in part at the 2010 Congress
of the European Society of Medical
Oncology, October 8-12, 2010, Milan,
Italy, and the Society of NeuroOncology 15th Annual Scientific Meeting, November 18-21, 2010, Montreal,
Quebec, Canada.
Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this
article.
Clinical trial information: NCT00777153.
Corresponding author: Tracy Batchelor,
MD, Stephen E. and Catherine Pappas
Center for Neuro-Oncology, Yawkey 9E,
Massachusetts General Hospital Cancer
Center, 55 Fruit St, Boston, MA 02114;
e-mail: tbatchelor@partners.org.
© 2013 by American Society of Clinical
Oncology
0732-183X/13/3126w-3212w/$20.00

A

B

S

T

R

A

C

T

Purpose
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in
Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib,
an oral pan–vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as
monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma.
Patients and Methods
Patients (N ⫽ 325) with recurrent glioblastoma who previously received radiation and
temozolomide were randomly assigned 2:2:1 to receive (1) cediranib (30 mg) monotherapy; (2)
cediranib (20 mg) plus lomustine (110 mg/m2); (3) lomustine (110 mg/m2) plus a placebo. The
primary end point was progression-free survival based on blinded, independent radiographic
assessment of postcontrast T1-weighted and noncontrast T2-weighted magnetic resonance
imaging (MRI) brain scans.
Results
The primary end point of progression-free survival (PFS) was not significantly different for either
cediranib alone (hazard ratio [HR] ⫽ 1.05; 95% CI, 0.74 to 1.50; two-sided P ⫽ .90) or cediranib in
combination with lomustine (HR ⫽ 0.76; 95% CI, 0.53 to 1.08; two-sided P ⫽ .16) versus
lomustine based on independent or local review of postcontrast T1-weighted MRI.
Conclusion
This study did not meet its primary end point of PFS prolongation with cediranib either as
monotherapy or in combination with lomustine versus lomustine in patients with recurrent
glioblastoma, although cediranib showed evidence of clinical activity on some secondary end
points including time to deterioration in neurologic status and corticosteroid-sparing effects.

DOI: 10.1200/JCO.2012.47.2464

J Clin Oncol 31:3212-3218. © 2013 by American Society of Clinical Oncology

INTRODUCTION

Despite recent advances in radiation and neurosurgical techniques and the approval of new medical therapies, glioblastoma, the most common
primary malignant brain tumor in adults, causes
significant neurologic morbidity and is associated
with survival of less than 2 years.1,2 Microvascular
proliferation, a pathologic hallmark of glioblastoma,
is due to the high expression of proangiogenic
cytokines, particularly of vascular endothelial
growth factor (VEGF) and signaling via its endothelial tyrosine kinase receptor VEGFR2.3-6 Levels
of VEGF and its receptor are correlated with the
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histologic grade of gliomas, with the highest levels
present in glioblastoma.7,8Thus glioblastoma has
emerged as an attractive tumor in which to conduct clinical trials of novel anti-VEGF agents,
such as monoclonal antibodies and tyrosine
kinase inhibitors.9Bevacizumab, an anti-VEGF
monoclonal antibody, was approved as monotherapy for recurrent glioblastoma by the US
Food and Drug Administration in 2009 based on
the radiographic response rates in two phase
II trials.10-12
Cediranib is an orally available pan-VEGFR tyrosine kinase inhibitor with a half-life of 22 hours
compatible with once daily dosing. Cediranib has a
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sub-nanomolar half maximal inhibitory concentration for VEGF receptors with additional activity against c-Kit and lower potency
against platelet-derived growth factor ␤.13 In a prior phase II study of
cediranib (45 mg/d) for patients with recurrent glioblastoma, eight
(27%) of 30 subjects achieved a partial radiographic response based
on consensus-based response criteria.14,15 Subsequently, this international, phase III, randomized, partially blinded, placebo-controlled study
was conducted to investigate the efficacy of cediranib, as monotherapy
and in combination with the synthetic alkylating agent lomustine (1-(2chloroethyl)-3-cyclohexyl-1-nitrosourea), versus lomustine alone in patients with recurrent glioblastoma.
PATIENTS AND METHODS
Patients
Patients with recurrent glioblastoma were the target population for this
study. Inclusion criteria included age ⱖ 18 years, pathologic diagnosis of
glioblastoma, prior treatment with a temozolomide-containing chemotherapy regimen, prior treatment with radiation, Karnofsky performance status
(KPS) ⱖ 70, Mini-Mental Status Examination score ⱖ 15, and life expectancy ⱖ 12 weeks. Exclusion criteria included any prior anti-VEGF therapy or
cranial radiation within 3 months before study entry. All patients were required to sign an informed consent form approved by the institutional review
board of the enrolling institution.
The study was performed in accordance with the Declaration of Helsinki,
the International Conference on Harmonization/Good Clinical Practice, applicable (national) regulatory requirements, and the AstraZeneca policy
on bioethics.

Trial Design and Treatments
The study was a phase III, comparative, randomized, parallel group,
multicenter trial with patients randomly assigned (stratified by age and resection status) in a 2:2:1 ratio to receive cediranib (30 mg) monotherapy, cediranib (20 mg) in combination with lomustine (110 mg/m2), or lomustine (110
mg/m2) in combination with a placebo. Cediranib doses (20 mg, 30 mg) were
given once daily as oral tablets, lomustine doses (110 mg/m2) were given as oral
capsules once every 6 weeks, and cediranib-matched placebo was given once
daily as oral tablets. The primary end point of the study was to compare the
efficacy of cediranib, as monotherapy and in combination with lomustine,
with lomustine alone by independent, treatment arm– blinded, radiographic
assessment of progression-free survival (PFS). Secondary objectives included
assessments of the proportion of patients alive and progression-free at 6
months (APF6) after randomization, overall survival (OS), radiographic response rate, corticosteroid-sparing effects, time to deterioration in neurologic
status (TTNS), safety, and tolerability. Exploratory end points included the
time to deterioration in KPS and changes from baseline in the levels of soluble
markers of angiogenesis and tumor growth.
Evaluations
The primary PFS end points were determined in patients on a stable dose
of corticosteroids, based on postcontrast, T1-weighted brain magnetic resonance imaging (MRI) scans assessed by independent, centralized, treatment
arm-blinded, radiographic review. The central PFS assessment took corticosteroid dose and timing of scans into account. The PFS end points were also
assessed by local review of postcontrast, T1-weighted MRI brain scans by the
treating physicians as well as independent, centralized, treatment-arm
blinded, radiographic review of T2/fluid-attenuated inversion recovery MRI
brain scans on the basis of published criteria.16,17 For patients with measurable
disease at study entry (defined as contrast-enhancing tumor with a shortest
diameter of ⱖ 10 mm on two axial slices), progression was defined as either

Assessed for eligibility
(N = 423)

Excluded
Did not meet inclusion criteria
Voluntary discontinuation
Death

(n = 98)
(n = 93)
(n = 3)
(n = 2)

Patients randomly assigned
(n = 325)

Cediranib 30 mg
Allocated to intervention
(n = 131)
Received allocated intervention
(n = 128)
Did not receive allocated intervention (n = 3)
Voluntary discontinuation
(n = 2)
Incorrect enrollment
(n = 1)

Cediranib 20 mg + lomustine
Allocated to intervention
(n = 129)
Received allocated intervention
(n = 123)
Did not receive allocated intervention (n = 6)
Voluntary discontinuation
(n = 1)
Incorrect enrollment
(n = 5)

Placebo + lomustine
Allocated to intervention
(n = 65)
Received allocated intervention
(n = 64)
Did not receive allocated intervention (n = 1)
Voluntary discontinuation
(n = 0)
Incorrect enrollment
(n = 1)

Lost to follow-up
Discontinued intervention
Death
Voluntary discontinuation
Incorrect enrollment
Ongoing at data cut-off

Lost to follow-up
Discontinued intervention
Death
Voluntary discontinuation
Incorrect enrollment
Ongoing at data cut-off

Lost to follow-up
Discontinued intervention
Death
Voluntary discontinuation
Incorrect enrollment
Ongoing at data cut-off

(n = 3)
(n = 34)
(n = 33)
(n = 0)
(n = 1)
(n = 28)

Full analysis set (ITT)
Analyzed
Excluded from analysis

(n = 65)
(n = 0)

Full analysis set (ITT)
Analyzed
Excluded from analysis

(n = 3)
(n = 87)
(n = 85)
(n = 1)
(n = 1)
(n = 41)

(n = 131)
(n = 0)

Full analysis set (ITT)
Analyzed
Excluded from analysis

(n = 4)
(n = 79)
(n = 73)
(n = 1)
(n = 5)
(n = 46)

(n = 129)
(n = 2)

Fig 1. CONSORT diagram. ITT, intent to treat.
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(1) ⱖ 25% increase in the sum of the products of the largest perpendicular
diameters for all lesions compared with the nadir scan (provided that the
shortest diameter was ⱖ 15 mm at the time of progression); (2) detection of a
new lesion, with shortest diameter of ⱖ 10 mm, outside the original tumor
volume; (3) death from any cause. For postsurgical patients without measurable disease at study entry, progression was defined as either (1) detection of a
new lesion; (2) a significant increase in lesion size (to a shortest diameter of
ⱖ 15 mm) for a small, baseline enhancing lesion at study entry; (3) death from
any cause. The neurologic status and KPS were based on physical examination
by the treating investigator before and during treatment. Corticosteroid doses
were recorded for all subjects. Plasma samples obtained at baseline and during
the study were used to determine levels of the soluble biomarkers VEGF,
sVEGFR2, and basic fibroblast growth factor (bFGF) and to calculate changes
from baseline levels. Adverse events (AEs) were recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Statistical Analysis
The primary end point of the study was PFS based on centralized,
radiographic review. Secondary end points were OS, response rate in patients
with measurable disease, APF6, time to deterioration in neurologic status,
mean change in average daily dosage of corticosteroids, and average number of
progression- and corticosteroid-free days. Assuming a true hazard ratio (HR)
of 0.55, with 300 patients randomly assigned 2:2:1 to cediranib, cediranib plus
lomustine, and lomustine plus placebo, the trial had more than 80% power to
demonstrate a statistically significant difference in PFS at a two-sided, 2.5%
level. This would correspond to an 80% increase in PFS if median time to
progression was 3 months in the lomustine-alone arm. The analysis for PFS
was planned after 230 progression events had occurred. PFS was analyzed
using the log-rank test, stratified by resection status and age, and the HR of
progression and associated 95% CIs were estimated from a Cox proportional
hazards model using stratification levels as covariates. Each cediranibcontaining arm was independently compared with the lomustine plus placebo
arm. Statistical significance would be declared if both comparisons were significant at the two-sided 5% level or if either comparison was statistically
significant at the two-sided 2.77% level. OS was planned to be analyzed
twice—at the time of PFS analysis and again when 270 deaths had occurred. To
maintain an overall type I error rate of 5%, the significance level was prespecified at 0.00785 (two-sided) at interim for both comparisons and at 0.00417
(two-sided) at interim for either comparison. All efficacy assessments were
performed on the intent-to-treat randomly assigned population.

RESULTS

Patients
Between October 2008 and September 2009, 325 patients were
randomly assigned in a ratio of 2:2:1 to receive cediranib (30 mg)
monotherapy (n ⫽ 131), cediranib (20 mg) plus lomustine (110
mg/m2) n ⫽ 129), or lomustine (110 mg/m2) plus placebo (n ⫽ 65). A
CONSORT diagram is included in Figure 1. The demographic and
baseline clinical characteristics were generally well-balanced across the
three arms, although fewer patients in the lomustine plus placebo arm
had KPS less than 80 and used corticosteroids at baseline (Table 1).
Efficacy Outcomes
The primary end point of PFS was not significantly different for
either cediranib alone or in combination with lomustine versus lomustine alone. For the cediranib (30 mg) monotherapy arm, the HR
versus lomustine was 1.05 (95% CI, 0.74 to 1.50; two-sided P ⫽ .90).
For the cediranib (20 mg) plus lomustine arm, the HR versus lomustine was 0.76 (95% CI, 0.53 to 1.08; two-sided P ⫽ .16). The median
PFS for the cediranib (30 mg) monotherapy arm, the cediranib (20
mg) plus lomustine arm, and the lomustine arm was 92 days (first
3214

Table 1. Baseline Characteristics
Cediranib
(n ⫽ 131)
Characteristic

No.

Median age, years
Resection for recurrent
disease
Yes
No
Karnofsky performance
status
⬍ 70
70-80
90-100
Corticosteroid use at
baseline
Yes
No
Time from last radiotherapy
to randomization,
months
0-3
3-6
6-12
⬎ 12

54.0

%

Cediranib ⫹
Lomustine
(n ⫽ 129)
No.

%

54.0

Lomustine
⫹ Placebo
(n ⫽ 65)
No.

%

54.0

50
81

38.2
61.8

49
80

38.0
62.0

24
41

36.9
63.1

0
65
65

50.0
50.0

1
62
66

0.8
48.0
51.2

1
23
40

1.6
36.2
62.5

64
67

48.9
51.1

71
58

55.0
45.0

26
39

40.0
60.0

2
32
52
45

1.5
24.4
39.7
34.4

4
29
42
54

3.1
22.5
32.6
41.9

0
16
27
22

24.6
41.5
33.8

quartile ⫽ 80 days, third quartile ⫽ 128 days), 125 days (first quartile ⫽ 83 days, third quartile ⫽ 201 days), and 82 days (first quartile ⫽
42 days, third quartile ⫽ 168 days), respectively (Fig 2). Compared
with the lomustine arm, neither cediranib-containing arm demonstrated a significant improvement in PFS based on either central
review of postcontrast T1-weighted or noncontrast T2/ fluidattenuated inversion recovery brain MRI scans or local review of
postcontrast T1-weighted brain MRI scans. At the time of the primary
PFS analysis, approximately 73% (197 of 270) of the death events
prespecified for final analysis had occurred. At this time, there was no
significant difference in the secondary end point of OS for either
cediranib-containing arm versus the lomustine arm. For the cediranib
(30 mg) monotherapy arm, the HR versus lomustine was 1.43 (95%
CI, 0.96 to 2.13; two-sided P ⫽ .10). For the cediranib (20 mg) plus
lomustine arm, the HR versus lomustine was 1.15 (95% CI, 0.77 to
1.72; two-sided P ⫽ .50). The median OS for the cediranib (30 mg)
monotherapy arm, the cediranib (20 mg) plus lomustine arm, and the
lomustine arm was 8.0 months, 9.4 months, and 9.8 months, respectively (Fig 3). On the basis of predictive power calculations, there was
less than a 0.01% chance of concluding a positive outcome at the final
OS analysis; thus it was considered of no value to continue to final
analysis. A total of 136 patients received postprogression anticancer
therapy, with the majority receiving bevacizumab either as monotherapy or in combination. Postprogression bevacizumab utilization
was similar in the cediranib (20 mg) plus lomustine (43 of 84, 51%)
and the lomustine plus placebo (20 of 39, 51%) arms but was less
frequent in the cediranib (30 mg) open-label, monotherapy arm (22 of
81, 27%).
There were no differences in the radiographic response rates
between the two cediranib-containing arms (Table 2). The median
reduction in contrast-enhanced tumor area was ⫺36% and ⫺28% in
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Progression-Free Survival (%)

100
Ced
Ced + lom
Pla + lom

n

Events

131
129
65

109 (83%)
98 (77%)
44 (68%)

Median PFS (days) HR v lom (95% CI)
92
125
82

1.05 (0.74 to 1.50)
0.76 (0.53 to 1.08)

P
.90
.16

80

60

40

Fig 2. Progression-free survival (PFS;
based on central review postcontrast T1).
No. at risk denotes the number of patients
who were event free at the beginning of
the period. Ced, cediranib; HR, hazard
ratio; lom, lomustine; Pla, placebo.

Ced 30 mg
Ced 20 mg + lom 110 mg/m2
Pla 20 mg + lom 110 mg/m2

20

0

21

42

63

84

105 126 147 168 189 210 231 252 273 294 315 336 357 378 399

Time Since Random Assignment (days)
No. at risk
Ced 30 mg
Ced 20 mg + lom
Pla + lom

131 122
129 117
65 60

114
110
47

76
78
23

100
89
29

50
59
19

35
52
16

15
40
12

20
41
12

14
27
10

10
22
8

7
16
7

6
15
5

the cediranib (30 mg) monotherapy and cediranib (20 mg) plus lomustine arms, respectively, compared with a ⫹14% increase in the
lomustine plus placebo arm (Fig 4). The APF6 proportions in the
cediranib (30 mg) monotherapy, cediranib (20 mg) plus lomustine,
and lomustine arms were 16%, 35%, and 25%, respectively. Corticosteroid usage was reduced in the cediranib-containing arms compared
with the lomustine arm; the mean change in corticosteroid use from
baseline to progression was ⫺26% for the cediranib (30 mg) monotherapy arm (P ⫽ .01 v lomustine), ⫺23% for the cediranib (20 mg)

n
Ced
Ced + lom
Pla + lom

Events

131
129
65

Median OS (months)

HR v lom (95% CI)

P

8.0
9.4
9.8

1.43 (0.96 to 2.13)
1.15 (0.77 to 1.72)

.10
.50

86 (66%)
77 (60%)
34 (52%)

Overall Survival (%)

100

5
6
3

4
5
3

4
4
3

1
2
2

1
2
1

0
1
1

plus lomustine arm (P ⫽ .01 v lomustine), and ⫹5% for lomustine.
The TTNS HRs for the cediranib (30 mg) monotherapy arm and the
cediranib (20 mg) plus lomustine arm versus lomustine were 0.82
(95% CI, 0.55 to 1.22; P ⫽ .57) and 0.63 (95% CI, 0.42 to 0.95; P ⫽
.01), respectively. The time to deterioration of KPS HRs for the cediranib (30 mg) monotherapy arm and the cediranib (20 mg) plus
lomustine arm versus lomustine were 1.03 (95% CI, 0.65 to 1.62) and
0.73 (95% CI, 0.45 to 1.17), respectively.
Soluble Biomarkers
Median baseline levels of VEGF were 74 pg/mL (first quartile ⫽
47, third quartile ⫽ 149), 76 pg/mL (first quartile ⫽ 46, third quartile ⫽ 165), and 66 pg/mL (first quartile ⫽ 34, third quartile ⫽ 93) in
the cediranib 30 mg, cediranib 20 mg plus lomustine, and lomustine
arms, respectively. Median VEGF levels in the cediranib 30-mg arm
increased to 89%, 108%, and 106% above baseline at days 42, 84, and

80
Table 2. Best Overall Response (central review postcontrast T1)

60

40
Ced 30 mg
Ced 20 mg + lom 110 mg/m2
Pla 20 mg + lom 110 mg/m2

20

0

2

4

6

8

10

12

14

16

18

Time Since Random Assignment (months)
No. at risk
Ced 30 mg
131
Ced 20 mg + lom 129
Pla + lom
65

122
122
62

99
109
54

72
97
44

51
63
34

33
35
19

20
21
9

7
8
3

1
2
1

Fig 3. Overall survival (OS). No. at risk denotes the number of patients who
were event free at the beginning of the period. Ced, cediranib; HR, hazard
ratio; lom, lomustine; Pla, placebo.
www.jco.org

6
8
4

Cediranib
(n ⫽ 118)

Cediranib ⫹
Lomustine
(n ⫽ 122)

Lomustine ⫹
Placebo
(n ⫽ 56)

Best Overall
Response

No.

%

No.

%

No.

%

Responders
CR
PR
Stable disease
Unconfirmed CR
Unconfirmed PR
PD
Nonevaluable

18
1
17
76
0
32
10
14

15.3
0.8
14.4
64.4

21
2
19
67
1
9
19
14

17.2
1.6
15.6
54.9
0.8
7.4
15.6
11.5

5
0
5
23
0
2
41.1
5

8.9

27.1
8.5
11.9

8.9
41.1
3.6
8.9

Abbreviations: CR, complete response; PD, progressive disease; PR,
partial response.
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B

400

C

400

400

350

350

300

300

300

250
200
150
100
50

Best Change in Tumor Size (%)

350

Best Change in Tumor Size (%)

Best Change in Tumor Size (%)

A

250
200
150
100
50

250
200
150
100
50

0

0

0

-50

-50

-50

-100

-100

-100
(n = 104)

(n = 103)

(n = 52)

Median: -35.7%
(Median first scan: -29.5%)

Median: -27.5%
(Median first scan: -17%)

Median: +14.4%
(Median first scan: +18%)

Fig 4. Best change from baseline in contrast-enhancing area. (A) Cediranib; (B) cediranib plus lomustine; (C) placebo plus lomustine.

126, respectively. By contrast, in the lomustine arm, median VEGF
levels at day 42 were similar to those at baseline and decreased by
21% at day 84. An increase in VEGF levels was also recorded at each
time point in the cediranib 20 mg plus lomustine arm (day 42,
46%; day 84, 41%; day 126, 61%), although these median increases
were lower than those for the cediranib 30-mg arm. Subgroup
analyses showed that baseline VEGF levels did not have a significant effect on either PFS or OS outcome. Median baseline levels of
sVEGFR2 were similar in the three arms (range, 10,937 to 11,790
pg/mL). At day 42, decreases in median sVEGFR2 levels from
baseline of 27% and 22% were recorded for the cediranib 30 mg
and cediranib 20 mg plus lomustine arms, respectively; these decreases were maintained in both arms at days 84 and 126. Median
sVEGFR2 levels in the lomustine arm remained similar to baseline
levels throughout the trial. Median baseline levels of bFGF were 5
pg/mL, 4 pg/mL, and 3 pg/mL in the cediranib 30 mg, cediranib 20
mg plus lomustine, and lomustine arms, respectively. No consistent changes from baseline in bFGF levels were seen in any arm. At
day 84, increases of 100% and 80% were observed in the lomustine
arm and the cediranib 20 mg plus lomustine arm, respectively, but
these increases were not maintained at day 126.
Dose-Intensity
The dose-intensity of cediranib was well maintained, and there
was no evidence of early discontinuation before progression in either
cediranib-containing arm. The mean dose-intensity was consistent
(⬃80%) during the first 3 months of therapy. There were more cediranib dose interruptions in the cediranib (20 mg) plus lomustine arm
versus the cediranib (30 mg) monotherapy arm. However, there were
more cediranib dose reductions in the cediranib (30 mg) monotherapy arm versus the cediranib (20 mg) plus lomustine arm, and the
3216

majority of reductions occurred after 3 months. The incidence of dose
interruptions and reductions of lomustine was higher in combination
with cediranib compared with placebo (although the number of cycles
of lomustine received was generally greater in the combination arm,
reflecting later progressions compared with the placebo arm). At least
one dose interruption of lomustine occurred in 27% of patients in the
placebo arm versus 40% in combination with cediranib. The dose of
lomustine was reduced in 50% of subjects on the lomustine plus
placebo arm versus 70% of subjects on the lomustine plus cediranib arm.
Safety and Tolerability
There were no unexpected AEs observed in any arm during the
course of the study. There was no increased risk of intracranial bleeding observed in the cediranib-containing arms. The most common AE
was diarrhea, experienced by 71%, 71%, and 19% of patients in the
cediranib monotherapy, cediranib plus lomustine, and lomustine
arms, respectively. AEs ⱖ grade 3 were experienced by a higher proportion of patients in the cediranib plus lomustine arm (80%) compared with the cediranib monotherapy and lomustine arms (61% in
each arm; Table 3). Grade 3 or 4 thrombocytopenia and neutropenia
were observed in 38% and 20%, respectively, of patients in the cediranib combination arm compared with 2% and 1%, respectively, in
the cediranib monotherapy arm and 22% and 3%, respectively, in the
lomustine arm.
Serious AEs were observed in 43%, 37%, and 41% of patients in
the cediranib monotherapy, cediranib plus lomustine, and lomustine
arms, respectively. AEs leading to permanent discontinuation of cediranib or placebo were observed in 15%, 18%, and 16% of patients in
the cediranib monotherapy, cediranib plus lomustine, and lomustine
arms, respectively.
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Table 3. Grade 3 and 4 AEs (safety population)
Cediranib
(n ⫽ 128)

Cediranib ⫹
Lomustine
(n ⫽ 123)

Placebo ⫹
Lomustine
(n ⫽ 64)

AE

No.

%

No.

%

No.

%

Any AE, ⱖ grade 3
Thrombocytopenia
Neutropenia
Fatigue
Leukopenia
Platelet count decreased
Anemia
Hypertension
ALT increased
GGT increased
WBC decreased
Diarrhea
Pulmonary embolism
Lymphopenia
Convulsion
Intracranial hemorrhage

78
2
1
21
1
0
0
18
3
1
0
8
4
3
11
0

60.9
1.6
0.8
16.4
0.8

98
47
25
19
14
10
8
8
7
7
7
7
6
5
2
1

79.7
38.3
20.3
15.4
11.4
8.1
6.5
6.5
5.7
5.7
5.7
5.7
4.9
4.1
1.6
0.8

39
14
2
6
3
1
0
0
0
2
3
1
4
5
3
2

60.9
22
3.1
9.4
4.7
1.6

14.1
2.3
0.8
6.3
3.1
2.3
8.6

3.1
4.7
1.6
6.3
7.8
4.7
3.1

Abbreviations: AE, adverse event; GGT, ␥-glutamyltransferase.

DISCUSSION

The REGAL trial failed to meet its primary end point of demonstrating
a benefit in PFS for either cediranib-containing arm versus lomustine
in patients with recurrent glioblastoma. Cediranib demonstrated
some clinical activity in certain secondary end points, including significant reduction of corticosteroid usage in both cediranibcontaining arms, and there was a favorable delay in time to neurologic
deterioration in the cediranib plus lomustine arm versus lomustine.
There was no difference in OS between the three arms. Although OS may
have been confounded by the use of postprogression bevacizumab therapy, bevacizumab use was similar between the cediranib 20 mg plus
lomustine and placebo plus lomustine arms. Expected, dose-dependent
increases in VEGF and decreases in sVEGFR2 were observed in the
cediranib-containingarmsbutnotinthelomustinearm.Baselinelevelsof
these soluble biomarkers were not predictive of outcome in this trial.
Dose-intensity of cediranib was well maintained in the cediranibcontaining arms, although there were more lomustine reductions in the
cediranib plus lomustine arm versus the lomustine arm despite the lower
dose of cediranib (20 mg) in the lomustine plus cediranib arm. The AE
profile observed in REGAL was consistent with prior cediranib trials, and
no unexpected AEs were observed. However, patients in the cediranib
plus lomustine arm experienced a higher incidence of toxicities, especially
hematologic adverse effects, compared with the cediranib monotherapy
and lomustine arms. This suggests that the combination of cediranib and
lomustine exacerbates lomustine-induced hematologic toxicities. The increased incidence of toxicities did not result in an increase of cediranib
discontinuations, suggesting that the toxicities were manageable. Importantly, no increased risk of intracranial bleeding was noted in patients
receiving cediranib.
The combination dose of cediranib (20 mg) was reduced from 30
mg after results from the National Cancer Institute of Canada BR24
study of metastatic lung carcinoma suggested a higher fatality rate in
www.jco.org

the cediranib-containing arms at this dose level.18 Whether selection
of a lower dose of cediranib in the REGAL study may have contributed
to the negative results of the study is impossible to determine.
Lomustine was approved in 1977 for use in patients with brain
tumors.19,20 In a phase I study it was observed that lomustine 130
mg/m2 in combination with cediranib (20 mg) was insufficiently well
tolerated in the population of patients with recurrent glioblastoma
who had received prior temozolomide therapy. The dose-limiting
toxicities were hematologic. It was determined that the optimal combination dose of lomustine for REGAL was 110 mg/m2, a dose also
used in other studies in this patient population.21 The PFS and APF6
observed in the lomustine arm in the REGAL study were higher than
the metrics typically used for comparative purposes from historical
series of therapies for this patient population but consistent with that
observed for lomustine in another control arm in a phase III study.22,23
However, it is noteworthy that patients were enrolled in REGAL at the
time of first recurrence, whereas these historical series included patients treated at the first, second, or later recurrences. Nevertheless,
lomustine monotherapy demonstrates efficacy in patients with recurrent glioblastoma previously treated with temozolomide and should
be considered as a control arm in future comparative trials.
Although cediranib monotherapy or in combination with lomustine did not improve PFS compared with lomustine alone in
REGAL, preclinical models suggest synergistic activity of anti-VEGF
therapy in combination with radiation owing to the ability of these
agents to normalize tumor vessels. On the basis of these observations,
cediranib in combination with chemoradiotherapy is being studied in
phase II trials in the newly diagnosed glioblastoma population24
(NCT00662506; NCT01062425).
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